BINYAMINA, Israel, June 21, 2022 /PRNewswire/ — OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, today announced a peer-reviewed article published in Journal for Immunotherapy of Cancer (JITC), a BMJ oncology journal. The study highlights the role of blood plasma proteomic profiling for assessing resistance in non-small cell lung cancer (NSCLC) patients being treated with immune checkpoint inhibitors (ICIs).

Read more here.